● Recruiting

A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

Condition: Dilated Cardiomyopathy · Sponsor: AstraZeneca

PhasePhase 1

Planned participants31

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with phospholamban (PLN) R14del dilated cardiomyopathy.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (4)

Research Site	Amsterdam, Netherlands	Recruiting
Research Site	Groningen, Netherlands	Recruiting
Research Site	Rotterdam, Netherlands	Recruiting
Research Site	Utrecht, Netherlands	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07241104